FDA Staff Recommend Against Adding Seven Peptides to the 503A Compounding List
Ahead of the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026, the agency’s pre-meeting briefing materials propose the same conclusion for every peptide under review: do not add it to the section 503A Bulk Drug Substances List. That list governs which raw drug substances licensed pharmacists and physicians may use to compound medications for individual patients.
Seven substances are on the agenda, each considered in free-base and acetate forms. BPC-157, KPV, TB-500, and MOTS-c are scheduled for discussion on July 23; emideltide (also called DSIP), Semax, and Epitalon on July 24. Across all seven, FDA’s documents describe the substances as not well-characterized, lacking meaningful human evidence of effectiveness for the proposed (mostly injectable) routes, and lacking sufficient human safety data — including unassessed immunogenicity risk.
The recommendations are staff proposals, not final decisions. A PCAC vote is advisory only; even a favorable vote would require FDA to proceed through formal notice-and-comment rulemaking before a substance could be added to the 503A list, and the agency is not bound by the committee’s recommendation.
Two participation windows apply for anyone following the docket: the request-to-present deadline has passed, and written comments intended to reach committee members before the meeting are due July 9, 2026. The meeting is being held at FDA’s White Oak campus in Silver Spring, Maryland, with a virtual attendance option.
Related reading: Several of the peptides under review have detailed entries in the VialHelp peptide library, including BPC-157, TB-500, MOTS-c, Semax, and Epitalon. For background on evaluating peptide quality, see our guide on how to read a Certificate of Analysis.
Share this article
For informational and educational use only — not medical advice. Intended for adults 21+.